We recently published a list of Top 10 Insider Sales Last Month. In this article, we are going to take a look at where ...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.

Independent Advisor Alliance increased its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 64.7% during the ...

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is ...

Equities research analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for Cencora in a note issued to investors on Wednesday, February 26th. Zacks Research analyst I.

Reports Q1 revenue $81.5B, consensus $78.22B. “Cencora (COR) delivered an excellent start to fiscal 2025 as we focused on advancing our core capabilities and enhancing our value proposition ...